Navigation Links
Inverness Medical Innovations, Inc. Announces Offering of $200 Million of Senior Subordinated Notes
Date:5/4/2009

WALTHAM, Mass., May 4 /PRNewswire-FirstCall/ -- Inverness Medical Innovations, Inc. (NYSE: IMA), a global leader in enabling individuals to take charge of their health at home through the merger of rapid diagnostics and health management, today announced that it intends to offer $200 million of senior subordinated notes due 2016 in a public offering. Payment of the notes will be guaranteed by certain of Inverness' domestic subsidiaries. Inverness intends to use the net proceeds from the offering primarily for general corporate purposes.

UBS Investment Bank, Goldman, Sachs & Co. and Banc of America Securities LLC will act as joint book-running managers for the offering. Canaccord Adams, Leerink Swann and Stifel Nicolaus will serve as co-managers.

The offering will be made under Inverness' shelf registration statement on Form S-3 filed with the SEC on April 10, 2009. Inverness intends to file with the SEC later today a preliminary prospectus supplement and accompanying prospectus for the offering to which this communication relates. Before you invest, you should read the preliminary prospectus supplement, the accompanying prospectus, and the other documents we have filed with the SEC for more complete information about us and the offering. You may obtain these documents for free by visiting EDGAR on the SEC website at www.sec.gov. Alternatively, a copy of the preliminary prospectus supplement and accompanying prospectus may be obtained from UBS Securities LLC at 677 Washington Boulevard, Stamford, CT 06901, Attention: High Yield Syndicate or at 1-203-719-7991, from Goldman, Sachs & Co. at 85 Broad Street, New York, NY 10004, Attention: Prospectus Department, or at 1-866-471-2526, or Banc of America Securities LLC, at 100 West 33rd Street, 3rd Floor, New York, NY 10001, Attention: Prospectus Department, or at 1-800-294-1322.

This press release is neither an offer to sell nor a solicitation of an offer to buy the securities described herein, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction.

About Inverness

By developing new capabilities in near-patient diagnosis, monitoring and health management, Inverness Medical Innovations enables individuals to take charge of improving their health and quality of life at home. Inverness' global leading products and services, as well as its new product development efforts, focus on infectious disease, cardiology, oncology, drugs of abuse and women's health. Inverness is headquartered in Waltham, Massachusetts.

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the federal securities laws, including statements regarding the expected offering and the use of proceeds. These statements reflect Inverness' current views with respect to future events and are based on management's current assumptions and information currently available. Actual results may differ materially due to numerous factors including, without limitation, risks associated with market and economic conditions. Inverness undertakes no obligation to update any forward-looking statements contained herein.


'/>"/>
SOURCE Inverness Medical Innovations, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Inverness Medical Innovations Announces First Quarter 2009 Results
2. Inverness Medical Innovations Schedules Conference Call for 10:00 a.m. ET April 27, 2009 to Discuss First Quarter 2009 Results
3. Inverness Medical Innovations to Participate at Goldman Sachs Leveraged Finance Healthcare Conference on April 8, 2009
4. Eli Y. Adashi, MD, MS, FACOG, Joins Inverness Medical Innovations Board of Directors
5. Inverness Medical Innovations Launches New FDA Cleared C. DIFF QUIK CHEK COMPLETE(TM) Rapid Test
6. Inverness Medical Innovations to Pay April Series B Dividend in Additional Shares of Series B Stock
7. Inverness Medical Innovations Agrees to Acquire Second Territory Rapid Diagnostics Business of ACON
8. Inverness Medical Innovations Announces Fourth Quarter 2008 Results
9. Inverness Medical Innovations Schedules Conference Call for 10:00 a.m. ET February 18, 2009 to Discuss Fourth Quarter 2008 Results
10. James Roosevelt, Jr. Joins Inverness Medical Innovations Board of Directors
11. Inverness Medical Innovations to Present at the 2009 UBS Global Healthcare Services Conference on February 10, 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... Los Angeles, CA (PRWEB) , ... February 23, 2017 , ... ... the first two episodes of WE TV’s “Mama June: From Not to Hot,” which ... of TV notable, “Mama” June Shannon, known to millions from the 2012 reality television ...
(Date:2/23/2017)... (PRWEB) , ... February 23, 2017 , ... ... thought leadership , media relations, content marketing, social media management, corporate communications, ... clients already in the state and in nearby New Hampshire, Massachusetts and Canada, ...
(Date:2/23/2017)... Los Angeles, California (PRWEB) , ... February 23, ... ... for Global Sports Development will host a diverse symposium on “Doping ... School of Law and Sheppard Mullin Richter & Hampton LLP. The symposium will ...
(Date:2/23/2017)... ... February 23, 2017 , ... ... new, interactive publication where generations converge and explore the world from different perspectives. ... Dialog Magazine enables readers to gain understanding, increase empathy, and find greater happiness. ...
(Date:2/23/2017)... ... February 23, 2017 , ... Current Meditation , ... begin franchising throughout the U.S. starting this spring. Current Meditation focuses on “meditation ... meditation mainstream. Current Meditation will be the first meditation concept in the U.S. ...
Breaking Medicine News(10 mins):
(Date:2/23/2017)... Feb. 23, 2017 Nevro Corp. (NYSE: NVRO), a ... for the treatment of chronic pain, today reported financial results ... 2016. 2016 Accomplishment & Highlights: ... 2016, an increase of 228% as reported, over the prior ... an increase of 612% over the prior year ...
(Date:2/23/2017)... Feb. 23, 2017 Research and Markets has ... Strategies - 2016" report to their offering. ... The latest research Fibromyalgia Drugs ... benchmarks in the global Fibromyalgia market. The research answers ... drugs marketed for Fibromyalgia and their clinical attributes? How are they ...
(Date:2/23/2017)... , February 23, 2017 ... Market by Product (X-ray Imaging Digital, Analog), MRI (Closed, ... (OB/GYN, MSK, Cardiology, Oncology), End User (Hospitals, Imaging Centers) ... report studies the global market over the forecast period ... reach ~USD 36.43 Billion by 2021, at a CAGR ...
Breaking Medicine Technology: